United States Securities and Exchange Commission
Washington, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )
BIOSTAR ANGEL STEM CELL CORPORATION
(Name of Issuer)
Common Stock
(Title of Class of Securities)
None
(CUSIP Number)
419 Hindry Avenue, Suite E
Inglewood, California 90301
-------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 16, 2018
-----------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D,
and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f)
or 240.13d-1(g), check the following box. [ ]
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
======================================================================
CUSIP NO. None 13D Page 2
1. Name of Reporting Persons: R BIO CO., LTD.
-------------------------------------------------------------------
2. Check the appropriate box if a member of a group:
(a)
(b)
-------------------------------------------------------------------
3. SEC use only
-------------------------------------------------------------------
4. Sourt of Funds PF
-------------------------------------------------------------------
5. Check if disclosure of legal proceeding is required pursuant
to Itmes 2(d) or 2(e) [ X ]
-------------------------------------------------------------------
6. Citizenship or place of organization: Republic of Korea
-------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7. Sole Voting Power: 2,000,000 shares common directly
owned
-------------------------------------------------------------------
8. Shared Voting Power: 0
-------------------------------------------------------------------
9. Sole Dispositive Power: 2,000,000 shares
-------------------------------------------------------------------
10. Shared Dispositive Power: 0
-------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
2,000,000 shares common
-------------------------------------------------------------------
12. Check if The Aggregate Amount in Row 11 Excludes Certain Shares.
/ / [ ]
-------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row 11
18.7%
(based on 10,680,000 shares outstanding)
-------------------------------------------------------------------
14. Type of Reporting Person: Corporation
======================================================================
CUSIP NO. None 13D Page 3
Item 1 Security and Issuer
(a) Name of Issuer: Biostar Angel Stem Cell Corporation
(b) Address of Issuer's 419 Hindry Avenue, Suite E
Inglewood, CA 90201
(c) Common stock, $0.0001 par value per share
-------------------------------------------------------------------
Item 2 Identity and Background
(a) Name of Person Filing: R Bio Co. Ltd
(b) Address of Principal Business or, if none, Residence:
Geumcheon-gu, Gasan Digital 2-ro 98,
Lotte IT Castle #2-305
Seoul, Republic of Korea 08506
(c) Principal occupation or employment: manufacturing and
sales of life science products such as cell and stem
cell products, together with the cell culturing agent.
Also engages in research and development on stem cell
related science.
(d) In 2015, R Bio Co. Ltd. was found guilty in the Seoul Southern
District Court, affirmed in 2017 by the Seoul High Court-
Court of Appeals of (i) violation of customs regulations
(Korean Customs Code Article 270, 269 and 241), (ii) violation
of foreign currency exchange regulations (Korean Foreign
Currency Exchange Code Article 28 and 18), and (iii) violation
of pharmaceutical regulations (Korean Pharmacist Code
Article 93 and 31). R Bio Co.Ltd. was fined approximately
USD $50,000. R Bio Co. Ltd has appealed the matter to
the Supreme Court of Korea which has accepted to hear the
case, and when the Supreme Court of Korea renders its
judgment, such judgment will then become the final judgment
on these matters.
(e) During the last five years, R Bio Co. Ltd. has not been a
party to a civil proceeding of a judicial or administrative
body of competent jurisdiction which as a result of such
proceeding was or is subject to a judgment, decree, or
final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state
securities laws or finding any violation with respect to
such laws.
(f) Citizenship: Republic of Korea
-------------------------------------------------------------------
Item 3. Source and Amount of Funds or Other Consideration
corporate funds
-------------------------------------------------------------------
Item 4. Purpose of transaction
invesment in issuer with change in control of company
-------------------------------------------------------------------
Item 5. Interest in Securities of Issuer
(a) As of the filing date of the Schedule 13D, R Bio Co Ltd.
(i) is the beneficial owner and
(ii) has sole power to vote
(iii) 2,000,000 shares of common stock which represents
approximately 18.7% of the shares of common stock
deemed to be outstanding pursuant to
Rule 13d-1(j).
(b) The responses to Items 7-11 of the cover page of this Schedule 13D are
incorporated herein.
(c) Except as set forth or incorporated herein, no other transaction in the
common stock has been effected during the past 60 days.
(d) Not applicable.
(e) Not applicable.
-------------------------------------------------------------------
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
Not applicable.
-------------------------------------------------------------------
Item 7. Materials to Be Filed as Exhibits
Not applicable.
-------------------------------------------------------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
R BIO CO., LTD.
Dated: March 6, 2018 By: /s/ Ra, Jeong-Chan
--------------------------------------
Ra, Jeong-Chan